Herpes zoster ophthalmicus temporally after COVID-19 vaccination: a systematic review of uncontrolled case reports and case series
- PMID: 39712418
- PMCID: PMC11657098
- DOI: 10.1080/08998280.2024.2426439
Herpes zoster ophthalmicus temporally after COVID-19 vaccination: a systematic review of uncontrolled case reports and case series
Abstract
Purpose: Herpes zoster ophthalmicus (HZO) following COVID-19 vaccination has been reported previously but the clinical characteristics, onset, treatment, and outcomes of these cases have not been previously systematically reviewed.
Methods: A systematic review, guided by PRISMA guidelines, surveyed PubMed and Embase databases from April 2021 to June 2023 for case reports and series detailing HZO following COVID-19 vaccination. Studies excluded were abstracts, reviews, and clinical trials. A subsequent descriptive analysis was performed, focusing on patient demographics, clinical characteristics, and outcomes.
Results: Sixteen publications involving 27 participants who developed HZO post-COVID-19 vaccination met the inclusion criteria. The onset of HZO averaged 13 days (SD 12) postvaccination, predominantly after the first dose (n = 20/27 HZO cases, 74%). Most patients (70%) had preexisting medical conditions. Antiherpetic antiviral therapy was utilized in all cases, with the majority achieving resolution of cutaneous and ocular symptoms. Long-term sequelae included postherpetic neuralgia in 7.4% of patients.
Conclusion: Cases of HZO following COVID-19 vaccination generally mirror the clinical trajectory of HZO in general. This review focused on case reports describing HZO occurring in an interval postvaccination; neither association nor causation can be addressed methodologically.
Keywords: COVID-19 vaccination; herpes zoster ophthalmicus; systematic review; varicella-zoster virus.
Copyright © 2024 Baylor University Medical Center.
Conflict of interest statement
Andrew G. Lee, MD, has served as a speaker for Amgen and Alexion; is on the Advisory Board for Viridian; and is a consultant for Stoke, AstraZeneca, and Bristol Myers Squib. All other authors report no conflicts of interest.
Similar articles
-
Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis.Cornea. 2023 Jun 1;42(6):731-738. doi: 10.1097/ICO.0000000000003246. Epub 2023 Jan 25. Cornea. 2023. PMID: 36706232
-
Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity.Ophthalmology. 2008 Feb;115(2 Suppl):S3-12. doi: 10.1016/j.ophtha.2007.10.009. Ophthalmology. 2008. PMID: 18243930 Review.
-
Herpes Zoster Ophthalmicus: Presentation, Complications, Treatment, and Prevention.Infect Dis Ther. 2024 Jul;13(7):1439-1459. doi: 10.1007/s40121-024-00990-7. Epub 2024 Jun 4. Infect Dis Ther. 2024. PMID: 38834857 Free PMC article. Review.
-
Risk of Herpes Zoster Ophthalmicus After COVID-19 Vaccination in a Large US Health Care Claims Database.Am J Ophthalmol. 2024 Feb;258:139-144. doi: 10.1016/j.ajo.2023.07.004. Epub 2023 Jul 7. Am J Ophthalmol. 2024. PMID: 37423396 Free PMC article.
-
Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States.Ophthalmology. 2021 Dec;128(12):1699-1707. doi: 10.1016/j.ophtha.2021.04.017. Epub 2021 Apr 20. Ophthalmology. 2021. PMID: 33892049 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Miscellaneous